Clinical Trial Update: Impact of 68Ga-DOTATATE PET/CT on the Management of Neuroendocrine Tumors: The Referring Physician's Perspective [EARLY_Phase 1]

View source ↗

Summary

An early-phase trial evaluates how 68Ga-DOTATATE PET/CT impacts clinical management of neuroendocrine tumors from the referring physicians' perspective.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Neuroendocrine Tumor

Drugs mentioned

• 68Ga-DOTATATE (Gallium-68 DOTATATE)

Snippet

Sponsor: Jonsson Comprehensive Cancer Center | Conditions: Neuroendocrine Tumors | EARLY_Phase 1 | Status: COMPLETED